CN115322971B - 一种鱼类圆环病毒及应用 - Google Patents
一种鱼类圆环病毒及应用 Download PDFInfo
- Publication number
- CN115322971B CN115322971B CN202210668958.2A CN202210668958A CN115322971B CN 115322971 B CN115322971 B CN 115322971B CN 202210668958 A CN202210668958 A CN 202210668958A CN 115322971 B CN115322971 B CN 115322971B
- Authority
- CN
- China
- Prior art keywords
- circovirus
- turbot
- fish
- strain
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001533384 Circovirus Species 0.000 title claims abstract description 54
- 241000157468 Reinhardtius hippoglossoides Species 0.000 claims abstract description 79
- 238000001514 detection method Methods 0.000 claims abstract description 31
- 241000251468 Actinopterygii Species 0.000 claims abstract description 25
- 229960005486 vaccine Drugs 0.000 claims abstract description 17
- 208000031169 hemorrhagic disease Diseases 0.000 claims abstract description 12
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 101100343677 Escherichia coli (strain K12) lon gene Proteins 0.000 claims description 5
- 101100219468 Staphylococcus aureus capF gene Proteins 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- 229940031626 subunit vaccine Drugs 0.000 claims description 5
- 229940031551 inactivated vaccine Drugs 0.000 claims description 4
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 238000009395 breeding Methods 0.000 abstract description 4
- 230000001488 breeding effect Effects 0.000 abstract description 4
- -1 pplication Species 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000269981 Bothidae Species 0.000 description 4
- 101150044789 Cap gene Proteins 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 208000005753 Circoviridae Infections Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 101150066583 rep gene Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- WZGZDOXCDLLTHE-SYWGBEHUSA-N Ala-Trp-Ile Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)NC(=O)[C@H](C)N)=CNC2=C1 WZGZDOXCDLLTHE-SYWGBEHUSA-N 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 description 1
- BEXGZLUHRXTZCC-CIUDSAMLSA-N Arg-Gln-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N BEXGZLUHRXTZCC-CIUDSAMLSA-N 0.000 description 1
- OFIYLHVAAJYRBC-HJWJTTGWSA-N Arg-Ile-Phe Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O OFIYLHVAAJYRBC-HJWJTTGWSA-N 0.000 description 1
- IICZCLFBILYRCU-WHFBIAKZSA-N Asn-Gly-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IICZCLFBILYRCU-WHFBIAKZSA-N 0.000 description 1
- FHETWELNCBMRMG-HJGDQZAQSA-N Asn-Leu-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FHETWELNCBMRMG-HJGDQZAQSA-N 0.000 description 1
- SYZWMVSXBZCOBZ-QXEWZRGKSA-N Asn-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)N)N SYZWMVSXBZCOBZ-QXEWZRGKSA-N 0.000 description 1
- JXGJJQJHXHXJQF-CIUDSAMLSA-N Asp-Met-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O JXGJJQJHXHXJQF-CIUDSAMLSA-N 0.000 description 1
- YFGUZQQCSDZRBN-DCAQKATOSA-N Asp-Pro-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YFGUZQQCSDZRBN-DCAQKATOSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000124892 Barbus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001533399 Circoviridae Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 101100326757 Drosophila melanogaster Capr gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- HHWQMFIGMMOVFK-WDSKDSINSA-N Gln-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O HHWQMFIGMMOVFK-WDSKDSINSA-N 0.000 description 1
- KWUSGAIFNHQCBY-DCAQKATOSA-N Gln-Arg-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O KWUSGAIFNHQCBY-DCAQKATOSA-N 0.000 description 1
- NPTGGVQJYRSMCM-GLLZPBPUSA-N Gln-Gln-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NPTGGVQJYRSMCM-GLLZPBPUSA-N 0.000 description 1
- MTCXQQINVAFZKW-MNXVOIDGSA-N Gln-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MTCXQQINVAFZKW-MNXVOIDGSA-N 0.000 description 1
- DYVMTEWCGAVKSE-HJGDQZAQSA-N Gln-Thr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O DYVMTEWCGAVKSE-HJGDQZAQSA-N 0.000 description 1
- NLKVNZUFDPWPNL-YUMQZZPRSA-N Glu-Arg-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O NLKVNZUFDPWPNL-YUMQZZPRSA-N 0.000 description 1
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 1
- DTPOVRRYXPJJAZ-FJXKBIBVSA-N Gly-Arg-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N DTPOVRRYXPJJAZ-FJXKBIBVSA-N 0.000 description 1
- DWUKOTKSTDWGAE-BQBZGAKWSA-N Gly-Asn-Arg Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DWUKOTKSTDWGAE-BQBZGAKWSA-N 0.000 description 1
- STVHDEHTKFXBJQ-LAEOZQHASA-N Gly-Glu-Ile Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STVHDEHTKFXBJQ-LAEOZQHASA-N 0.000 description 1
- GDOZQTNZPCUARW-YFKPBYRVSA-N Gly-Gly-Glu Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O GDOZQTNZPCUARW-YFKPBYRVSA-N 0.000 description 1
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 1
- IFHJOBKVXBESRE-YUMQZZPRSA-N Gly-Met-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CN IFHJOBKVXBESRE-YUMQZZPRSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- PDSUIXMZYNURGI-AVGNSLFASA-N His-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC1=CN=CN1 PDSUIXMZYNURGI-AVGNSLFASA-N 0.000 description 1
- YVCGJPIKRMGNPA-LSJOCFKGSA-N His-Met-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O YVCGJPIKRMGNPA-LSJOCFKGSA-N 0.000 description 1
- KYFGGRHWLFZXPU-KKUMJFAQSA-N His-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N KYFGGRHWLFZXPU-KKUMJFAQSA-N 0.000 description 1
- HGNUKGZQASSBKQ-PCBIJLKTSA-N Ile-Asp-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HGNUKGZQASSBKQ-PCBIJLKTSA-N 0.000 description 1
- KUHFPGIVBOCRMV-MNXVOIDGSA-N Ile-Gln-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N KUHFPGIVBOCRMV-MNXVOIDGSA-N 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- JQSXWJXBASFONF-KKUMJFAQSA-N Leu-Asp-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JQSXWJXBASFONF-KKUMJFAQSA-N 0.000 description 1
- VPKIQULSKFVCSM-SRVKXCTJSA-N Leu-Gln-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPKIQULSKFVCSM-SRVKXCTJSA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- HQXSFFSLXFHWOX-IXOXFDKPSA-N Lys-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCCCN)N)O HQXSFFSLXFHWOX-IXOXFDKPSA-N 0.000 description 1
- OIYWBDBHEGAVST-BZSNNMDCSA-N Lys-His-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OIYWBDBHEGAVST-BZSNNMDCSA-N 0.000 description 1
- VMTYLUGCXIEDMV-QWRGUYRKSA-N Lys-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN VMTYLUGCXIEDMV-QWRGUYRKSA-N 0.000 description 1
- DLAFCQWUMFMZSN-GUBZILKMSA-N Met-Arg-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N DLAFCQWUMFMZSN-GUBZILKMSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MPGJIHFJCXTVEX-KKUMJFAQSA-N Phe-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O MPGJIHFJCXTVEX-KKUMJFAQSA-N 0.000 description 1
- BRDYYVQTEJVRQT-HRCADAONSA-N Phe-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O BRDYYVQTEJVRQT-HRCADAONSA-N 0.000 description 1
- FXPZZKBHNOMLGA-HJWJTTGWSA-N Phe-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FXPZZKBHNOMLGA-HJWJTTGWSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000202347 Porcine circovirus Species 0.000 description 1
- ORPZXBQTEHINPB-SRVKXCTJSA-N Pro-Arg-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1)C(O)=O ORPZXBQTEHINPB-SRVKXCTJSA-N 0.000 description 1
- VVEQUISRWJDGMX-VKOGCVSHSA-N Pro-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3 VVEQUISRWJDGMX-VKOGCVSHSA-N 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- NLQUOHDCLSFABG-GUBZILKMSA-N Ser-Arg-Arg Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NLQUOHDCLSFABG-GUBZILKMSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- PXQUBKWZENPDGE-CIQUZCHMSA-N Thr-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)N PXQUBKWZENPDGE-CIQUZCHMSA-N 0.000 description 1
- FDALPRWYVKJCLL-PMVVWTBXSA-N Thr-His-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O FDALPRWYVKJCLL-PMVVWTBXSA-N 0.000 description 1
- WPRVVBVWIUWLOH-UFYCRDLUSA-N Tyr-Phe-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N WPRVVBVWIUWLOH-UFYCRDLUSA-N 0.000 description 1
- RGJZPXFZIUUQDN-BPNCWPANSA-N Tyr-Val-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O RGJZPXFZIUUQDN-BPNCWPANSA-N 0.000 description 1
- QGFPYRPIUXBYGR-YDHLFZDLSA-N Val-Asn-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N QGFPYRPIUXBYGR-YDHLFZDLSA-N 0.000 description 1
- CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 1
- ZRSZTKTVPNSUNA-IHRRRGAJSA-N Val-Lys-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(O)=O ZRSZTKTVPNSUNA-IHRRRGAJSA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 238000009364 mariculture Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
Abstract
本发明首次提出了一种新的大菱鲆圆环病毒及其应用,菌株TCV保藏于中国典型微生物保藏中心,保藏编号CCTCC No.V202232,全基因组序列如SEQ ID TCVfull所示;本发明同时提供一种鱼类圆环病毒的应用,为TCV病毒制得的疫苗,抗体,杂交瘤细胞,抗血清,检测试剂盒中的一种或多种;可提高大菱鲆养殖业中的出血病预防,有效检测和治疗大菱鲆养殖业中的出血病。
Description
技术领域
本发明属于病毒领域,具体讲,涉及一种新的鱼类圆环病毒及其应用。
背景技术
圆环病毒属于圆环病毒科圆环病毒属,基因组为单股负链环状DNA,全长1700bp左右,目前已知的最小DNA病毒之一。圆环病毒的宿主范围很广,包括猪、鸟类、犬、牛、小鼠等。2011年,在匈牙利的发病鲃鱼(Barbus barbus)鱼苗中首次发现鱼类中也存在圆环病毒感染的情况,但尚不能确定这种圆环病毒感染是否与鱼类的死亡有关。在鱼类中,由圆环病毒感染造成的死亡情况尚无报道。
大菱鲆是我国重要的海水养殖鱼类,广泛养殖于山东、河北和辽宁沿海地区,年产量接近7万吨,是我国北方沿海地区工厂化养殖的重要组成部分。但近年来,大菱鲆养殖受到一系列病害的困扰。2019年,一种突发的“出血病”对大菱鲆养殖造成了严重的影响,主要症状为鱼鳍出血、溃烂,并迅速大量死亡。该病传染速度极快,1-2个月内可以造成整个养殖鱼棚几十万尾大菱鲆全部死亡,给养殖户造成严重损失。目前,该病在全国各个养殖区均有发现,已成为大菱鲆养殖产业发展的严重屏障。
发明内容
本发明目的在于首次提出了一种新的大菱鲆圆环病毒及其应用。
本发明是通过以下技术方案实现的:
为实现上述目的,本发明提供一种鱼类圆环病毒,其特征在于:菌株TCV保藏于中国典型微生物保藏中心,保藏编号CCTCC No.V202232,全基因组序列如SEQ ID TCVfull所示。该病毒衣壳蛋白与已知的圆环病毒氨基酸同源性低于30%,复制蛋白同源性低于70%,定义为圆环病毒属的新种。
本发明同时提供一种鱼类圆环病毒的应用,为TCV病毒制得的疫苗,抗体,杂交瘤细胞,抗血清,检测试剂盒中的一种或多种。
优选的,上述疫苗为为圆环病毒减毒活疫苗、圆环病毒灭活疫苗、圆环病毒多肽疫苗或圆环病毒基因工程疫苗。
优选的,上述圆环病毒灭活疫苗包括亚单位疫苗。
优选的,上述疫苗用于预防和/或治疗大菱鲆出血病。
优选的,上述抗体,杂交瘤细胞,抗血清通过TCV菌株的裂解成分、该病毒株的基因工程蛋白或该病毒株的多肽为免疫原进行制备。
优选的,上述检测试剂盒包括抗原检测试剂盒、抗体检测试剂盒和核酸检测试剂盒。
优选的,上述抗原检测试剂盒中的抗原选自TCV病毒株的裂解成分、病毒株的基因工程蛋白或病毒株的多肽中的至少一种;抗体检测试剂盒中的抗体选自TCV病毒株的裂解成分、病毒株的基因工程蛋白或病毒株的多肽制备的单抗或多抗中的至少一种;核酸检测试剂盒包括普通PCR、实时荧光PCR中的至少一种。
优选的,上述核酸检测试剂盒采用的检测序列为如SEQ ID No:3所示。
与现有技术相比,本发明的有益效果在于:
(1)本发明首次提出了此种圆环病毒。
(2)通过制备此种圆环病毒的疫苗,可大大提高大菱鲆养殖业中的出血病预防。
(3)通过TCV病毒制备的抗体,杂交瘤细胞,抗血清,可有效治疗大菱鲆养殖业中的出血病。
(4)通过TCV病毒制备的核酸检测试剂盒,可以有效检测大菱鲆的病症。
附图说明
图1为本发明所述的圆环病毒基因组结构;
图2为本发明所述的圆环病毒基因组系统发育进化树;
图3为本发明所述的圆环病毒PCR检测结果;其中1.DNA Marker,2-4.山东地区因出血病死亡的大菱鲆组织DNA,5-6.山东地区发病养殖场其他养殖池中的大菱鲆组织DNA,7.空孔,8-9.辽宁地区因出血病死亡的大菱鲆组织DNA,10-12.健康大菱鲆组织DNA;
图4为本发明病毒拷贝数与Ct值之间的线性关系;
图5为本发明荧光定量PCR扩增曲线;
图6为本发明荧光定量PCR熔解曲线;
图7为本发明人工感染后大菱鲆肾脏中TCV的拷贝数变化;
图8为本发明实验室人工感染大菱鲆,其中箭头示鱼鳍出血;
图9为本发明发病大菱鲆肾脏电镜照片,其中箭头示病毒颗粒;
图10为本发明免疫后大菱鲆死亡率;
图11为本发明注射抗体后大菱鲆死亡率。
具体实施方式
下面结合实施例,更具体地说明本发明的内容。应当理解,本发明的实施并不局限于下面的实施例,对本发明所做的任何形式上的变通或改变都落入本发明保护范围;且下述实施例中的方法,如无特别说明,均为本领域的常规方法。
实施例1:
TCV病毒病毒株的分离和纯化
1.取2g带毒大菱鲆的肾脏加入到离心管中,10ml PBS在震荡器上强力震荡20分钟。
2.4℃、8000RPM离心20分钟,取上清作为粗纯化病毒悬液。
3.采用荧光定量PCR(探针法)检测病毒中圆环病毒的DNA载量
4.蔗糖梯度离心
利用蔗糖/甘油密度离心,38000rpm,离心6小时,收集甘油和30%蔗糖密度的样品,脱糖后作为纯化后抗原。
5.病毒序列的全基因组扩增:
利用PCR技术将病毒的Rep基因扩增后测序,经Genbank比对结果表明(图2),该病毒为圆环病毒的一个新种,TCV全基因组长1774bp,其序列如SEQ ID TCVfull所示;在此基础上设计引物对全基因组进行长片段的验证,保证序列的准确性。
经检验,其全基因序列如SEQ ID TCVfull所示(图1)。
分析TCV全基因序列,获得其Cap基因序列(SEQ ID TCVcap)和其Rep基因序列(SEQID TCVrep),留待后用。
实施例2:
圆环病毒TCV的PCR检测
根据大菱鲆圆环病毒的cap基因序列(SEQ ID TCVcap),利用Gene Bank网站,设计特异性引物capF(CCATGTCAAAGTTGACCTG)和capR(AGCAGAAGGGCGTGGATTG)。扩增病毒capsid基因序列如SEQ ID NO:3所示。
从养殖场挑选临床出血症明显的大菱鲆,按照海洋动物组织DNA提取步骤,提取大菱鲆肾脏DNA,以大菱鲆肾脏DNA作为模板,capF和capR作为引物,建立大菱鲆圆环病毒的普通PCR检测方法。PCR反应体系为Taq Mix 12.5μL,模板DNA 1μL,0.2μM的capF和capR引物各0.5μL,无菌双蒸水10.5μL。PCR反应条件为95℃预变性5min,95℃30s、55℃30s、72℃30s共计40个循环,72℃延伸5min。PCR检测结果如图3所示,所有发病样品均可检测到目的条带,健康样品中检测不到目的条带。将PCR产物克隆至T载体,构建大菱鲆圆环病毒绝对定量PCR检测质粒载体。
以capF和capR作为引物,以大菱鲆组织DNA作为模板,建立大菱鲆圆环病毒的荧光定量检测方法。PCR反应体系为SYBR Green Real-Time PCR Master Mixes 10μL,模板DNA1μL,0.2μM的capF和capR引物各1μL,无菌双蒸水8μL。PCR反应条件为98℃预变性1min,95℃15s、58℃15s、72℃30s共计40个循环,升温检测溶解曲线。以质粒载体为模板,建立病毒拷贝数与Ct值之间的线性关系(图4)。荧光定量PCR扩增曲线和熔解曲线如图所示,各个阳性样品均可检测到荧光信号(图5),熔解温度在85℃左右(图6),阴性对照没有检测到荧光信号。检测灵敏度超过普通PCR检测方法,并且可以进行病毒的定量检测,并可以根据公式确定组织内病毒的拷贝数:y=-4.5714x+40.478;R2=0.9972。
因此,通过TCV病毒制备的核酸检测试剂盒,采用特异性引物capF(CCATGTCAAAGTTGACCTG)和capR(AGCAGAAGGGCGTGGATTG),根据荧光信号可知样品是否阳性,并可以Ct值,获得病毒拷贝数,据此可以有效检测大菱鲆的病症。
实施例3:
大菱鲆圆环病毒的人工感染试验
挑选临床中出血症明显的大菱鲆,取发病鱼的肾脏,一部分提取组织DNA利用荧光定量PCR确定病毒的拷贝数,另一部分研磨、0.22μM滤膜过滤,利用PBS调整病毒浓度为1×105copies/mL,注射感染健康大菱鲆,每尾鱼注射0.1mL,对照组注射同等剂量不含组织液的PBS。
攻毒后大菱鲆肾脏组织中病毒的拷贝数持续上升(图7),并出现鱼鳍出血溃烂症状(图8),与自然发病的症状一致,感染20天内死亡90%,电镜观察显示死亡大菱鲆组织内存在圆环病毒颗粒(图9)。对照组未发生死亡和体表出血的情况。
由此可知,保藏的病毒种,依然带有致病能力,能起到后续治疗的材料所用。
实施例4:
大菱鲆圆环病毒的亚单位疫苗的制备
根据大菱鲆圆环病毒cap基因序列信息(SEQ ID TCVcap),合成cap基因并连接至表达载体pET-32a中,原核表达大菱鲆圆环病毒蛋白rCap,表达蛋白的氨基酸序列如SEQ IDTCVpro所示。利用IPTG诱导rCap的表达,并进行浓缩纯化,采取注射和口服两种方式对大菱鲆进行免疫。注射免疫组每尾大菱鲆腹腔注射0.1mL蛋白纯化液,包含rCap蛋白1mg;口服免疫组每尾大菱鲆灌胃0.1mL蛋白纯化液,包含rCap蛋白5mg,2周后再重复灌胃一次。免疫组每组20尾鱼,对照组21尾。同时,采用市面上已有成熟产品的猪圆环病毒基因工程亚单位疫苗(易圆净)对大菱鲆进行了免疫。免疫后大菱鲆和对照组大菱鲆采用同样养殖条件,免疫28天后,按照实施例2的方式,对免疫组和对照组大菱鲆进行注射攻毒,攻毒后死亡情况如图10所示。注射免疫对大菱鲆的免疫保护率为94.17%,口服免疫对大菱鲆的免疫保护率为88.33%,易圆净对大菱鲆没有保护效果。
根据此实验结果可知,本发明的亚单位疫苗相较市售的猪圆环病毒疫苗能对大菱鲆起到显著有效的免疫保护效果。
实施例5:
注射和口服免疫接种大菱鲆时免疫剂量的确定的应用方式
按照实施例4的方式,表达rCap。梯度稀释rCap,采取注射和口服两种方式对大菱鲆进行免疫。注射免疫组每尾大菱鲆腹腔注射0.1mL蛋白纯化液,分别包含rCap蛋白0.1mg、0.5mg、1mg和2mg;口服免疫组每尾大菱鲆灌胃0.1mL蛋白纯化液,包含rCap蛋白1mg、5mg、10mg和20mg,2周后再重复灌胃一次。免疫组每组20尾鱼,对照组21尾。免疫后大菱鲆和对照组大菱鲆采用同样养殖条件,免疫28天后,按照实施例2的方式,对免疫组和对照组大菱鲆进行注射攻毒,注射免疫对大菱鲆的免疫保护率为0、41.66%、94.17%和94.17%,口服免疫对大菱鲆的免疫保护率为41.66%、88.33%、82.50%和94.17%。因此,当注射免疫剂量≥1mg或口服免疫剂量≥5mg时,疫苗均具有较好的免疫保护效果。
实施例6:
大菱鲆圆环病毒的抗体、杂交瘤细胞或抗血清的制备
TCV病毒制备引发针对该病毒或异源核苷酸序列的抗体,使用本领域技术人员已知的技术(例如,免疫亲和层析、离心、沉淀等)分离的抗体。
通过将表达本发明TCV病毒颗粒与等体积的完全弗氏佐剂(Sigma)采取注射和口服两种方式刺激大菱鲆而产生针对该TCV病毒的抗血清。每只大菱鲆隔两周后再次接种,四周后收集大菱鲆血清;这种大菱鲆抗体可以以下方式用于诊断目的或用作疫苗,可用作目标抗体用于检测针对该病毒的特异性抗原。不完全弗氏佐剂(Sigma)可添加于随后免疫中。抗体效价测定方法同灭活疫苗测定方法。
实施例7:
大菱鲆圆环病毒的抗体、杂交瘤细胞抗血清或卵黄抗体对出血症的治疗
按照实施例4的方式,表达rCap。将rCap蛋白与弗氏佐剂混合,免疫新西兰大白兔,两周后重复免疫1次,免疫后一个月,取兔血,离心收集血清,采用proteinA/G纯化得到大菱鲆圆环病毒Cap蛋白多克隆抗体。
按照实施例4的方式,表达rCap。将rCap蛋白与弗氏佐剂混合,免疫SPF小鼠,两周后重复免疫1次,免疫后一个月,取小鼠脾脏细胞,与小鼠骨髓瘤细胞进行细胞融合,制备小鼠杂交瘤细胞,并采用细胞培养的方式生产大菱鲆圆环病毒Cap蛋白单克隆抗体。
按照实施例4的方式,表达rCap。将rCap蛋白与弗氏佐剂混合,免疫SPF蛋鸡,两周后重复免疫1次,免疫后一个月,蛋黄提取卵黄抗体IgY。
按照实施例3的方式,对大菱鲆进行注射感染攻毒,攻毒后第三天,分别采用单克隆抗体、卵黄抗体对大菱鲆进行注射治疗,对照组注射同等剂量的PBS,大菱鲆死亡情况如图11所示:对照组大菱鲆全部死亡,单克隆抗体注射治疗存活率为80%,多克隆抗体注射治疗存活率为65%,抗体治疗组存活率均显著高于对照组。
根据此实验结果可知,上述抗体可以通过浸泡、口服或注射的方式,对大菱鲆圆环病毒进行预防或治疗。
以上所述之具体实施方式为本发明的较佳实施方式,并非以此限定本发明的具体实施范围,本发明的范围包括并不限于本具体实施方式,凡依照本发明所作的等效变化均在本发明的保护范围内。
SEQUENCE LISTING
<110> 中国水产科学研究院黄海水产研究所
<120> 一种鱼类圆环病毒及应用
<130> 12345678
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 1774
<212> DNA
<213> Turbot Circovirus
<400> 1
tggcatcaaa tgaatgcaag aataacagtg atttactttc ggtaagctta gtgaatgggt 60
ccccgtgagg gggccctagg aagccagccc caggaattct ctgaaggcta cgtatagctt 120
cacctccatg tcaaagttga cctgggtctg ctgccctctt tccatgaagt attgcatacc 180
ataatgcttt actgttaggt tgtcaccatt aatccagggt gatgctctca tcacgttgaa 240
gtttgtagag atccctcctt cttcagccgc catgtgtacc cttggtttga aaatacgtgt 300
gtgttttctg tttccaatcc acgcccttct gcttgacctt tgcagtagcg ggtcatcagt 360
tcccgctcca accgttctgc cgtcaaagtc aatggcagtt gatccatgag taatttcccc 420
tccggatccc gccagttgta taatggcagt tgactgcctt ggcctgaatg tcacaacaat 480
tagtgtaatc ctataatagt cccatggcag ccgtccagca aagtcaccca gtttgaagtc 540
tagttctccg ccctggctcc cggctttaat ttgcaaatta aaatgcctga tgaatcttgt 600
ctggaaacgc ccttgcgtga gtcctcctct ttgtctcacc gcaacattcc ttctgactct 660
catggctacg cctcttcttt gaggcctacg ccttcggtgt cccgcctggg cacgcattct 720
ccaacgtgta aacgcccttc ttaccctata aaagagaatg agaagttgca tagtattacc 780
agcaacttcg gcaccagaac cacactatgc ctaaatccag agaaaaccca gggaaaagat 840
ggtgtttcac tatcaaccat cctgactttg aggattactt agatgtagtc aattggttta 900
gacctaagac tgtcagctat gctgtttgcg gggaagagac cggcgaaagc ggtaccccgc 960
acctccaggg ttacttcaac ctccggagca agaaacgact ttctcagctg aagaatgagt 1020
tctcttcccg ggcacatctg gagccagccc gcggtactga aatgcaaaac aaggaatatt 1080
gtacgaagga aaaactttac ctggagaacg gcattccgac tggtcaagga gctcgcaacg 1140
atatctcttc agctgttgct gtcctggagg agtccggctt gactggtgtc gctgagaagt 1200
gccccgtcgc ttttatacgg taccaccgtg gcctgcaggc attgtccgac atccggcgat 1260
tggtcaagcc acgctacacc aagactcgac tgactgtgct tgtggggccc cctggctgtg 1320
gcaagagtcg ctgggccgct gaggaggccg ctaaaaatcc tgctggagcc aatgtgttct 1380
acaagagccg gggggagtgg tgggatgggt actttcaaca agatgttgtt gtaattgatg 1440
atttttatgg atggatgaaa tatgatgaac tgttacgtgt gtgtgacaga tacccacttc 1500
gtgttcctgt aaagggtgct tttcaggagt tcacctcatc ccacgtgatc attacaagca 1560
acaagcactt acatgagtgg tactcatttc ctggttttga ccctgaccct cttgtccgtc 1620
gtgtgaccaa ttacatggtt tgggatcaag gacttaatga ttgggtcgag caccaagatg 1680
gtgactggaa acgtggctct cttcgccgct tgtataatcc acatgcagtt gatcaataaa 1740
cacattacaa tgatttctgt ttctgaattt ttat 1774
<210> 2
<211> 642
<212> DNA
<213> Turbot Circovirus
<400> 2
atgcgtgccc aggcgggaca ccgaaggcgt aggcctcaaa gaagaggcgt agccatgaga 60
gtcagaagga atgttgcggt gagacaaaga ggaggactca cgcaagggcg tttccagaca 120
agattcatca ggcattttaa tttgcaaatt aaagccggga gccagggcgg agaactagac 180
ttcaaactgg gtgactttgc tggacggctg ccatgggact attataggat tacactaatt 240
gttgtgacat tcaggccaag gcagtcaact gccattatac aactggcggg atccggaggg 300
gaaattactc atggatcaac tgccattgac tttgacggca gaacggttgg agcgggaact 360
gatgacccgc tactgcaaag gtcaagcaga agggcgtgga ttggaaacag aaaacacaca 420
cgtattttca aaccaagggt acacatggcg gctgaagaag gagggatctc tacaaacttc 480
aacgtgatga gagcatcacc ctggattaat ggtgacaacc taacagtaaa gcattatggt 540
atgcaatact tcatggaaag agggcagcag acccaggtca actttgacat ggaggtgaag 600
ctatacgtag ccttcagaga attcctgggg ctggcttcct ag 642
<210> 3
<211> 208
<212> DNA
<213> Turbot Circovirus
<400> 3
ccatgtcaaa gttgacctgg gtctgctgcc ctctttccat gaagtattgc ataccataat 60
gctttactgt taggttgtca ccattaatcc agggtgatgc tctcatcacg ttgaagtttg 120
tagagatccc tccttcttca gccgccatgt gtacccttgg tttgaaaata cgtgtgtgtt 180
ttctgtttcc aatccacgcc cttctgct 208
<210> 4
<211> 213
<212> PRT
<213> Turbot Circovirus
<400> 4
Met Arg Ala Gln Ala Gly His Arg Arg Arg Arg Pro Gln Arg Arg Gly
1 5 10 15
Val Ala Met Arg Val Arg Arg Asn Val Ala Val Arg Gln Arg Gly Gly
20 25 30
Leu Thr Gln Gly Arg Phe Gln Thr Arg Phe Ile Arg His Phe Asn Leu
35 40 45
Gln Ile Lys Ala Gly Ser Gln Gly Gly Glu Leu Asp Phe Lys Leu Gly
50 55 60
Asp Phe Ala Gly Arg Leu Pro Trp Asp Tyr Tyr Arg Ile Thr Leu Ile
65 70 75 80
Val Val Thr Phe Arg Pro Arg Gln Ser Thr Ala Ile Ile Gln Leu Ala
85 90 95
Gly Ser Gly Gly Glu Ile Thr His Gly Ser Thr Ala Ile Asp Phe Asp
100 105 110
Gly Arg Thr Val Gly Ala Gly Thr Asp Asp Pro Leu Leu Gln Arg Ser
115 120 125
Ser Arg Arg Ala Trp Ile Gly Asn Arg Lys His Thr Arg Ile Phe Lys
130 135 140
Pro Arg Val His Met Ala Ala Glu Glu Gly Gly Ile Ser Thr Asn Phe
145 150 155 160
Asn Val Met Arg Ala Ser Pro Trp Ile Asn Gly Asp Asn Leu Thr Val
165 170 175
Lys His Tyr Gly Met Gln Tyr Phe Met Glu Arg Gly Gln Gln Thr Gln
180 185 190
Val Asn Phe Asp Met Glu Val Lys Leu Tyr Val Ala Phe Arg Glu Phe
195 200 205
Leu Gly Leu Ala Ser
210
Claims (10)
1.一种鱼类圆环病毒(Turbot Circovirus),其特征在于:菌株TCV保藏于中国典型微生物保藏中心,保藏编号CCTCC No.202232。
2.如权利要求1所述的鱼类圆环病毒,全基因组序列如SEQ ID No:1所示。
3.权利要求1所述的鱼类圆环病毒在制备疫苗,抗体,杂交瘤细胞,抗血清,检测试剂盒中的一种或多种的应用。
4.如权利要求3所述的鱼类圆环病毒的应用,其特征在于,所述疫苗为圆环病毒减毒活疫苗、圆环病毒灭活疫苗、圆环病毒多肽疫苗或圆环病毒基因工程疫苗。
5.如权利要求4所述的鱼类圆环病毒的应用,其特征在于,所述圆环病毒灭活疫苗包括亚单位疫苗。
6.如权利要求3所述的鱼类圆环病毒的应用,其特征在于,所述疫苗用于预防和/或治疗大菱鲆出血病。
7.如权利要求3所述的鱼类圆环病毒的应用,其特征在于,所述抗体,杂交瘤细胞,抗血清通过TCV菌株的裂解成分、该病毒株的基因工程蛋白或该病毒株的多肽为免疫原进行制备。
8.如权利要求3所述的鱼类圆环病毒的应用,其特征在于,所述检测试剂盒包括抗原检测试剂盒、抗体检测试剂盒和核酸检测试剂盒。
9.如权利要求8所述的鱼类圆环病毒的应用,其特征在于,所述抗原检测试剂盒中的抗原选自TCV病毒株的裂解成分、病毒株的基因工程蛋白或病毒株的多肽中的至少一种;抗体检测试剂盒中的抗体选自TCV病毒株的裂解成分、病毒株的基因工程蛋白或病毒株的多肽制备的单抗或多抗中的至少一种;核酸检测试剂盒包括普通PCR、实时荧光PCR中的至少一种。
10.如权利要求9所述的鱼类圆环病毒的应用,其特征在于,所述核酸检测试剂盒采用的检测序列引物为capF和capR,其序列分别为CCATGTCAAAGTTGACCTG和AGCAGAAGGGCGTGGATTG。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210668958.2A CN115322971B (zh) | 2022-06-14 | 2022-06-14 | 一种鱼类圆环病毒及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210668958.2A CN115322971B (zh) | 2022-06-14 | 2022-06-14 | 一种鱼类圆环病毒及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115322971A CN115322971A (zh) | 2022-11-11 |
CN115322971B true CN115322971B (zh) | 2023-10-10 |
Family
ID=83916307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210668958.2A Active CN115322971B (zh) | 2022-06-14 | 2022-06-14 | 一种鱼类圆环病毒及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115322971B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116376848B (zh) * | 2022-12-13 | 2024-07-16 | 中国水产科学研究院黄海水产研究所 | 一种卤虫病毒及其检测方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005112726A (ja) * | 2003-10-02 | 2005-04-28 | Meiji Seika Kaisha Ltd | ヒラメのウイルス性出血性敗血症に対するdnaワクチン |
CN111172325A (zh) * | 2020-02-21 | 2020-05-19 | 北京天恩泽基因科技有限公司 | 多靶点双染料等温扩增快速检测方法和试剂盒 |
CN113234647A (zh) * | 2021-07-13 | 2021-08-10 | 烟台市海洋经济研究院(烟台市渔业技术推广站、烟台市海洋捕捞增殖管理站) | 一株大菱鲆来源的杀鲑气单胞菌及其应用 |
CN114438263A (zh) * | 2022-02-22 | 2022-05-06 | 广州双螺旋基因技术有限公司 | 一种用于检测欧洲鳗鲡圆环病毒的荧光定量pcr引物组及试剂盒 |
CN114540258A (zh) * | 2022-04-25 | 2022-05-27 | 烟台市海洋经济研究院(烟台市渔业技术推广站、烟台市海洋捕捞增殖管理站) | 一株大菱鲆来源的杀鲑气单胞菌弱毒株及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10004797B2 (en) * | 2010-10-27 | 2018-06-26 | Harrisvaccines, Inc. | Method of rapidly producing improved vaccines for animals |
-
2022
- 2022-06-14 CN CN202210668958.2A patent/CN115322971B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005112726A (ja) * | 2003-10-02 | 2005-04-28 | Meiji Seika Kaisha Ltd | ヒラメのウイルス性出血性敗血症に対するdnaワクチン |
CN111172325A (zh) * | 2020-02-21 | 2020-05-19 | 北京天恩泽基因科技有限公司 | 多靶点双染料等温扩增快速检测方法和试剂盒 |
CN113234647A (zh) * | 2021-07-13 | 2021-08-10 | 烟台市海洋经济研究院(烟台市渔业技术推广站、烟台市海洋捕捞增殖管理站) | 一株大菱鲆来源的杀鲑气单胞菌及其应用 |
CN114438263A (zh) * | 2022-02-22 | 2022-05-06 | 广州双螺旋基因技术有限公司 | 一种用于检测欧洲鳗鲡圆环病毒的荧光定量pcr引物组及试剂盒 |
CN114540258A (zh) * | 2022-04-25 | 2022-05-27 | 烟台市海洋经济研究院(烟台市渔业技术推广站、烟台市海洋捕捞增殖管理站) | 一株大菱鲆来源的杀鲑气单胞菌弱毒株及其应用 |
Non-Patent Citations (4)
Title |
---|
"First detection and analysis of a fish circovirus";Márta Lőrincz等;《Journal of General Virologyrol》;第92卷(第8期);第1817-1821页 * |
"养殖大菱鲆爆发性疖疮的病原分离与组织病理研究";刘建男等;《大连海洋大学学报》;第35卷(第5期);第701-706页 * |
"养殖大菱鲆病原菌迟缓爱德华氏菌的分离鉴定及其疫苗研制";王燕等;《中国水产科学》;第16卷(第03期);第394-403页 * |
"圆环病毒Cap蛋白的研究进展";王钊哲等;《上海畜牧兽医通讯》(第03期);第19-21页 * |
Also Published As
Publication number | Publication date |
---|---|
CN115322971A (zh) | 2022-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112500458B (zh) | 鸡传染性法氏囊病病毒新型变异株亚单位疫苗、其制备方法及应用 | |
CN113337478B (zh) | 一株猫细小病毒毒株及其应用 | |
CN104962581B (zh) | 一种表达非洲猪瘟病毒p72蛋白的重组病毒疫苗株 | |
CN112063592A (zh) | 非洲猪瘟多基因联合缺失减毒株的构建及作为疫苗的应用 | |
CN114107228B (zh) | 缺失十二个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用 | |
CN108728490A (zh) | 一种基于杆状病毒载体的鲤疱疹病毒ii型dna疫苗及其构建方法与应用 | |
CN117625557B (zh) | 一株大口黑鲈(Micropterus salmoides)蛙虹彩病毒(Ranavirus sp.)及其应用 | |
CN108101967B (zh) | Ⅰ群血清4型禽腺病毒基因工程亚单位疫苗、制备方法及其应用 | |
CN113943714A (zh) | 一种猫杯状病毒毒株及其应用 | |
CN111593027B (zh) | 一种草鱼呼肠孤病毒ⅱ型弱毒株及其应用 | |
CN115322971B (zh) | 一种鱼类圆环病毒及应用 | |
CN105247043A (zh) | 鳞片脱落疾病(sdd)致病病毒及其衍生物 | |
CN114015660B (zh) | 缺失十个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用 | |
CN115851623A (zh) | 非洲猪瘟mgf505-2r基因缺失减毒株的构建及作为疫苗的应用 | |
CN114561366A (zh) | 一种山羊库布病毒分离株及其应用 | |
CN111773383B (zh) | 一种o型口蹄疫亚单位疫苗及其制备方法和应用 | |
CN109705223B (zh) | 一种羊口疮病毒重组亚单位疫苗及其生产方法 | |
KR20210022165A (ko) | 조류 레오바이러스 백신 | |
CN110462030B (zh) | 强毒性肠道病毒71的稳定生产及其利用 | |
CN114921422B (zh) | 一种犬源猫细小病毒分离株及其应用 | |
KR100977306B1 (ko) | 닭 전염성 f낭병 바이러스의 유전자 재조합 vp2단백질및 이를 포함하는 닭 전염성 f낭병 진단시약 | |
CN113855795B (zh) | 禽戊型肝炎病毒orf2亚单位疫苗 | |
CN116286686A (zh) | 双基因缺失减毒非洲猪瘟病毒株的构建及其作为疫苗的应用 | |
CN109517044B (zh) | 一种猪流行性腹泻病毒基因工程抗原和抗体 | |
CN109439633B (zh) | 一种插入h7n9的ha蛋白的新城疫病毒重组疫苗株 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |